Health costs of the UK-US trade deal on pharmaceuticals.

Billions diverted from NHS funding to pay for new drugs under the UK-US trade deal could cause thousands of excess deaths and harm public health.

• Why it matters: This work highlights the potential health risks of trade agreements that prioritize drug costs over public health, addressing a critical policy gap.
• What they did: The authors analyze the financial shift resulting from the trade deal, estimating that increased drug spending will divert substantial NHS funds, risking health outcomes.
• The result: The findings suggest that the trade deal may lead to significant public health deterioration, emphasizing the need for careful evaluation of its long-term health impacts.